A Case Report on Metastatic Thyroid Carcinoma: Radiation-induced Bystander or Abscopal Effect?

Slavisa Tubin*, Franco Casamassima, Claudia Menichelli, Gabriella Pastore, Alessandro Fanelli and Rossana Crisci
Istituto Ricerche Cliniche Ecomedica, Empoli, Florence, Italy

Abstract
For the first time the rare radiobiological phenomenon of spontaneous regression of an unirradiated tumor in a course of irradiation of other, distant lesion in a patient affected by thyroid carcinoma has been observed. Identifying tumors that are capable of inducing this phenomenon, and doses for which its intensity would be maximum, this effect could be exploited as a powerful weapon for radio-sensitize the regional or distant tumor and increase the control of it.

Keywords: Radiation induced abscopal effect; Radiation induced bystander effect; Thyroid cancer

Introduction
The effects of radiation on human tissues are not just local as once believed but they can appear even outside of the irradiated field [1-5]. Based on what has been published, both from in vitro and in vivo studies [6,7], it is known that those effects are at least regional. The irradiated tumor tissue may communicate, in some way, radiation effects to the not irradiated neighboring or distant tumor. If the irradiated tumor is forming a physical contact with a not irradiated tumor, then the phenomenon of transmission of the radiation damage is called “bystander effect”. The “abscopal effect” [8], on the other hand, refers to the phenomenon of damage communication between irradiated tumor and a distant tumor that has not been irradiated. The first report on abscopal effect dating from 1953 was published by Mole [1]. Thereafter many authors have published observations on in vivo abscopal effects in different tumor types, such as malignant melanoma [2], lymphoma [3], hepatocellular carcinoma [4], and cervical carcinoma [5]. So far no authors have published on such phenomena induced by thyroid carcinoma. This is the first case report on a radiation-induced abscopal effect in a thyroid cancer-patient.

Methods and Materials
The patient, a 72 year old Italian man, with negative family history for cancer, was diagnosed in 2007 with medullary thyroid carcinoma. He was treated at the “Endocrinology and Kidney-Integrated Activity Department” in Pisa, Italy. He is an ex smoker who stopped smoking in 1983, with a history of rheumatic aortic and mitral valve stenosis (with mechanical prosthesis implants), chronic atrial fibrillation (with a permanent pacemaker implant), benign prostatic hypertrophy, gastro-esophageal reflux, diverticular disease of sigma, arterial hypertension and chronic obstructive bronchopneumopathie. None has been previously subjected to radiation treatment.

In 2007 he underwent left supraclavicular lymph node biopsy due to swelling in that region. Pathological examination revealed a medullary thyroid carcinoma. He underwent total thyroidectomy with left neck, pretracheal and superior mediastinal lymph node dissection in January of 2008. Subsequent pathological examination confirmed multifocal, bilateral medullary thyroid carcinoma with maximum diameter of 2 cm, stage pT3 pN1b IVA; 16 of 31 examined lymph nodes were positive for metastases. Clinical staging at that time did not show any other lymph node or organ involvement.

Nine months later, in September of 2008, he underwent left infraclavicular lymph node dissection for the appearance of metastases in that region. In 2011, he was treated with an experimental drug inhibitor of tyrosine-kinase receptor (known as XL 184), for new disease progression at mediastinal lymph node levels 4R and 6. That treatment was carried out from February until March, when it was discontinued for the occurrence of important side effects.

He remained under close medical supervision. A CT-scan performed in March of 2012 showed further mediastinal lymph nodes enlargement at levels 4R and 6 that measured 29 × 28 mm and 66 × 48 mm, respectively. No other site involvement was found at that time.

The patient was given the option to again enter the experimental study with the inhibitor of tyrosine-kinase receptor, but considering the side effects during previous treatment he chose not to participate. Instead the patient was monitored closely, allowing the possibility of further treatment in case of disease progression. In June of 2012 he was hospitalized for worsening dyspnea, caused by obstruction of the bronchi by the mediastinal mass. At that time the CT scan showed the already known mediastinal lymphadenopathies to be larger than in the previous scans. Maximum diameter for the lymph node station level 4R was 40 mm vs. 29 mm and for the station level 6 was 80 mm vs. 66 mm. Due to his worsening condition, he was sent to our department for radiotherapy.

Examination of the patient revealed that his general condition was fair with Karnofsky performance status 90. He complained of moderate dyspnea and no other disorders. We decided to give him symptomatic radiotherapy treatment for the purpose of bronchial decompression. We defined the two symptomatic lymphadenopathies at the lymph node station level 4R and 6 (Figure 1) as the target for irradiation. Given that medullary thyroid carcinoma is a radioresistant disease, we

*Corresponding author: Slavisa Tubin, Istituto Ricerche Cliniche Ecomedica, Via Cherubini n.c. 2, 50053 Empoli, Florence, Italy, Tel: 0039-0571-992-765/0039-328-776-9106; Fax: 0039-0571-992-726; E-mail: s.tubin@radioterapia.ecomedica.it

Received October 25, 2012; Accepted November 21, 2012; Published November 23, 2012

Copyright: © 2012 Tubin S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
prescribed a total dose of 3000 cGy in 3 fractions to the 70% isodose line at the 4R lymph node level (the smaller lymphadenopathy group). We used the Volumetric modulated arc therapy (VMAT) technique and 6 megavolt energy photons. The Gross tumor volume (GTV) was contoured with an additional margin of 4 mm. We started the treatment on June 25th by irradiating the smaller volume at level 4R first, because of more evident bronchial compression on that site. The lymphadenopathy at level 6 was not irradiated at the time, and was located outside of the radiation field. Only a very low percentage of that lesion, precisely 5.97%, received 500 cGy in 3 fractions (Figure 2), and the received mean dose was 264 cGy.

**Results**

One month after that treatment, our patient returned to treat the other lymphadenopathy at level 6. A cone beam CT was performed before treatment, showing a size reduction of the treated lymphadenopathy 4R, indicating a partial response at the time. Surprisingly, the lymphadenopathy at level 6 had also reduced in size and to a greater degree than the treated 4R-lesion, thereby showing a response to “no treatment” (Figure 3). This untreated lesion had shrunk in anteroposterior (AP) and lateral (LL) directions with a maximum size reduction of 1.6 cm and a 32% volume reduction (171.5 cc vs. 117 cc). A simulation CT scan was repeated to re-plan the treatment for this lesion, which was then irradiated from August 14th to August 20th of 2012, with 4000 cGy in 5 fractions prescribed at 70% isodose line.

**Discussion**

Although, there are many published cases on radiation-induced abscopal effect, there has been no description in literature of such a phenomenon in a patient with primary thyroid cancer. It is unclear whether what we observed was an abscopal or bystander effect. What we do know is that we observed a partial response at the level of nodal mass irradiated unintentionally (with a very low dose that covered a very small percentage of its volume) as a result of irradiation of another distant metastatic lymph node lesion, without physical contact between them. There are no other plausible reasons which could trigger such a reaction because our patient neither received chemotherapy, nor drugs different from those with which he was being treated before the course of radiotherapy. As previously stated, the bystander effect denotes the transmission of radiation damage from irradiated tumor to adjacent non-irradiated tumor through inter-cellular gap junctions. Another mechanism of radiation damage “communication” from the irradiated tumor to the non-irradiated tumor occurs via “bystander factors”. In this model, soluble cytokine-like molecules would function as messengers between distant tumors, without a need for physical contact between them. While there are several techniques to demonstrate the mechanism of inter-tumor communication in response to irradiation in vitro [7], it is much more complex to demonstrate the responsible mechanisms in vivo due to the complexity of a system such as the human organism. The mechanisms of these phenomena have not been clearly understood. There are two mechanisms proposed by Lin et al. [9], the ischemia and immune response. Stamell et al. [10] have found an association between the abscopal effect and the systemic antitumor immune response in melanoma. Irradiating only the primary melanoma resulted in the complete response in all in-transit metastases and was associated with anti-MAGE-3 antimelanoma antibodies that were found upon serological testing. Other hypotheses have also been proposed. Hall et al. [11] suggested that in response to local irradiation there is an increase in the level of serum Tumor Necrosis Factor alpha,
which in turn mediates the antimitotic systemic effect even at sites distant from the irradiated tumor. The local irradiation could destroy tumor tissue and cause the release of tumor antigens into the systemic circulation. These antigens would be capable of stimulating the natural killer-mediated immune response, against a tumor, distant from the irradiation site that expresses the same antigens [12]. As we did not expect such an effect, we did not create a preemptive setup to measure the mechanisms involved.

We analyzed a lymphadenopathy size reduction in AP, LL and craniocaudal diameters, trying to understand if there was a correlation between a size reduction direction and dose distribution that covered "not irradiated" tumor. We expected that if the mechanism responsible for the response of the tumor was inter-cellular gap junction-mediated communication (bystander effect), then the gradient of the size reduction of the tumor should be more asymmetric or concentrated on the same side where that minimum dose reached the tumor (Figure 2). We did not find any such correlation. Maximum size reduction was found to be 1.6 cm in both directions, AP and LL; the CC tumor extension did not change. The tumor had shrunk in a uniform manner (Figure 4). The volume of lymphadenopathy measured before the radiotherapy treatment was 171.5 cc vs. 117 cc one month after irradiation of 4R lymph node level, which equals a 32% volume reduction. It is not only the size reduction that we observed, but also the increase in diameter of central tumor necrosis (Figure 4). It seems that a factor that reacted in response to radiation in the 4R, interacted with the non-irradiated tumor uniformly, indicating a mechanism more likely to be an abscopal effect. From another point of view, as the dose applied to this cancer was very low and covered just a small portion of its mass, it is unlikely that this could cause a bystander effect so powerful to reduce the volume of mass by 32%. Only 5.97% of tumor received 500 cGy in 3 fractions. The bystander effect is mainly observed in in vitro experiments on cell cultures as induction of sister-chromatid exchanges, mutations, neoplastic transformation, apoptosis, micronucleus, chromosomal aberrations and DNA double strand breaks, using very low doses of alpha particles (range: mGy, cGy) [13], but also after conventional irradiation (X-rays, gamma rays) at low as well as at conventional doses [14]. Of the limited number of in vivo accounts, some report that there was an observed bystander effect with dramatic reduction in tumor size, for a small number of patients whose large masses were irradiated partially in one fraction with high doses using GRID radiotherapy [15,16]. Peter et al. [17] reported on a robust abscopal effect caused by this technique in distant tumors that were not irradiated. The tumor in our case study was irradiated partially, in only two very small islands, each of which received 3 fractions of

![Figure 3: Cone beam CT shows size reduction in untreated lesion at level 6 one month after irradiation of lymphadenopathy at level 4R.](image)

![Figure 4: Size reduction and increase of central tumor necrosis of lymphadenopathy at level 6 before and after irradiation.](image)
167 cGy. That dose is much lower than that used in published studies on GRID radiotherapy; the irradiated volume (islands) was also much smaller. That would not be enough to cause a partial response for a tumoral mass with this volume. It would not fit with the current model and published data on linear cell killing. Bystander factors such as TNF-alpha [18,19], TRAIL [19] and Ceramide [20] are induced in cells that are under the open field of the high-dose GRID areas and are hypothesized to be responsible for initiating the cell death cascade both in the epithelial and endothelial compartments of the tumor micro-environment. It is reasonable to assume in our case that both effects were involved: bystander and abscopal.

Conclusion

We observed a rare radiobiological phenomenon of tumor shrinkage in a site distant to the area of irradiation, in a type of tumor previously not associated with these phenomena (medullary thyroid carcinoma). This tumor responded to signals induced by irradiation of the other distant tumor likely due to mixed bystander and abscopal effects. With a better understanding of factors responsible for the transmission of radiation-induced damage and which doses would be able to induce such an effect, we would have better guidelines for creating bystander and abscopal effects, to enhance control of micro- and macroscopic regional and distant disease.

References


Submit your next manuscript and get advantages of OMICS

Unique features:

• User friendly/feasible website-translation of your paper to 50 world’s leading languages
• Audio Version of published paper
• Digital articles to share and explore

Special features:

• 200 Open Access Journals
• 15,000 editorial team
• 21 days rapid review process
• Quality and quick editorial, review and publication processing
• Indexing at PubMed (partial), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc
• Sharing Options, Social Networking Enabled
• Authors, Reviewers and Editors rewarded with online Scientific Credits
• Better discount for your subsequent articles

Submit your manuscript at: www.editorialmanager.com/cancerscience/